多囊卵巢综合征相关子宫内膜癌的经济负担
采用PRISMA系统综述方法纳入9项研究,用随机效应模型评估多囊卵巢综合征(PCOS)患者子宫内膜癌(EndoCA)的合并风险比。
要点
- PCOS患者子宫内膜癌合并风险比为3.46(95%CI 2.28-5.23),P≤.001。
- 美国2020年PCOS患者子宫内膜癌患病率1.712%,全女性基线0.489%。
核心结论
- 子宫内膜癌虽为PCOS值得关注的疾病负担,但其归因经济负担仅占PCOS总医疗负担的一小部分。
研究设计与样本
- 采用PRISMA系统综述指南,评估PCOS患者子宫内膜癌发生率的研究。
- 排除综述、病例报告、非人类受试者、无对照、无全文或仅报告其他疾病的研究。
- 纳入研究采用纽卡斯尔-渥太华量表评估质量,Meta分析采用DerSimonian-Laird随机效应模型评估合并风险比(RR)。
- 共筛选98项研究,最终纳入9项。
主要发现
- PCOS患者子宫内膜癌合并RR为3.46(95%CI 2.28-5.23),P≤.001。
- 美国2020年PCOS患者子宫内膜癌患病率为1.712%,全女性基线估计患病率为0.489%。
- 归因于PCOS的子宫内膜癌超额患病率为1.223%,约98 348名受影响女性。
- PCOS对子宫内膜癌的人群归因分数为24.4%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive-aged females, and women with PCOS are at increased risk for endometrial cancer (EndoCA), the most common gynecological malignancy. OBJECTIVE: Our study sought to assess the economic burden associated with EndoCA in PCOS. METHOD: Using PRISMA systematic review guidelines, we evaluated studies on EndoCA rates in patients with PCOS. Excluded studies were reviews and case reports, those with nonhuman subjects, without controls, without full text available, or reporting solely on other conditions. Selected studies were assessed for quality using the Newcastle-Ottawa Scale. Meta-analysis used DerSimonian-Laird random effects model to assess pooled risk ratio (RR). Excess cost was assessed in US dollars (USD). RESULT: Of 98 studies screened, 9 were included. Pooled RR for EndoCA in PCOS was 3.46 (95% CI, 2.28-5.23), P ≤ .001. In the United States, prevalence of EndoCA in patients with PCOS in 2020 was 1.712%, compared with a baseline estimated prevalence in all women of 0.489%. The excess prevalence of EndoCA attributable to PCOS was 1.223%, approximately 98 348 affected women. A population attributable fraction of EndoCA for PCOS was 24.4%. Given estimated costs of EndoCA exceeding $1.9 billion (in 2023 USD), the economic burden of EndoCA attributable to PCOS exceeds $467 million/year. CONCLUSION: The excess annual US healthcare cost for EndoCA attributable to PCOS exceeds $467 million/year (2023 USD). Although a concerning morbidity of PCOS, it is notable that the economic burden of EndoCA attributable to the disorder represents only a small fraction of its total healthcare burden.
引用
- Pace L, Markovic D, Buyalos R, et al. Economic Burden of Endometrial Cancer Associated With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2024. PMID: 39106216. doi:10.1210/clinem/dgae527
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。